Business Wire

The LYCRA Company Opens Advanced Textile Innovation Center in China

Del

The LYCRA Company, a leading provider of fiber and technology solutions for the global apparel and personal care industries, announced today it will officially open its new Advanced Textile Innovation Center (ATIC) in Nanhai, China on May 16. The new 4,500-square-meter Research & Development (R&D) laboratory, which is the company’s fourth, represents a significant increase in the U.S.-based firm’s global R&D capabilities.

Scientists at the R&D center will help mills, brands and retailers throughout Asia, as well as Western-based companies with local sourcing offices, create innovative fabrics and garments using The LYCRA Company’s branded textile solutions, which include LYCRA® fiber, LYCRA HyFit® fiber, COOLMAX® fiber and THERMOLITE® fiber. The research team will also engage with customers in opportunity identification, as well as the development and commercialization of new polymer, fiber and textile technologies.

“Developing groundbreaking innovations and creating new garment categories are part of our company’s heritage and critical to our success going forward,” said Bob Kirkwood, chief technology officer. “Our investment in ATIC not only enhances our global R&D capabilities, but also demonstrates our commitment to providing exceptional service to our customers based in Asia.”

ATIC is fully equipped with commercial equipment to simulate real world manufacturing processes including knitting, weaving, dyeing and finishing. This will enable The LYCRA Company to deliver unmatched technical support to its customers, ensuring consistent product quality and helping to reduce risk. In addition, the lab has garment engineering, fabric certification and analytical testing tools to help customers achieve desired performance attributes for their fabrics or garments.

As part of the company’s Virtual Lab network, ATIC researchers will be able to collaborate seamlessly with colleagues in labs located across the globe to develop world-class innovations and apply best practices.

“By integrating science with apparel market research, ATIC staff will help guide the development and commercialization of innovative garment solutions designed to meet global apparel market needs,” said Julien Born, president, Apparel. “Co-locating ATIC and our South China sales office, will enable tighter integration between R&D and our commercial team and help our customers accelerate speed-to-market.”

The LYCRA Company, formerly INVISTA’s Apparel & Advanced Textiles business, has operated as an independent subsidiary of Shandong Ruyi since January 31. The company has retained its leadership team, and with the support of its primary shareholder, now has the ability to take The LYCRA Company to new heights.

Renowned for its history of transforming apparel and revolutionizing the fashion industry, The LYCRA Company’s customers can expect the same focus on compliance, quality, innovation, branding and marketing they have experienced in the past.

The company has operations in 14 countries including four R&D labs, eight manufacturing sites and 17 offices to serve its customers around the world. Its assets include over 1,000 patents and applications, over 2,300 registered trademarks and nearly 250 unique logos and brands.

About The LYCRA Company

The LYCRA Company innovates and produces fiber and technology solutions for the apparel and personal care industries, as well as specialty chemicals used in the spandex and polyurethane value chains. Headquartered in Wilmington, Delaware, The LYCRA Company is recognized worldwide for its innovative products, technical expertise, and unmatched marketing support. The LYCRA Company owns leading consumer and trade brands: LYCRA ® , LYCRA HyFit ® , LYCRA ® T400 ® , L by LYCRA ® , COOLMAX ® , THERMOLITE ® , ELASPAN ® , SUPPLEX ® , TACTEL ® , and TERATHANE ® . While The LYCRA Company’s name is new, its legacy stretches back to 1958 with the invention of the original spandex yarn, LYCRA ® fiber. Today, The LYCRA Company is focused on adding value to its customers’ products by developing unique innovations designed to meet the consumer’s need for comfort and lasting performance. For more information, visit www.connect.lycra.com and www.lycra.com .

LYCRA ® , HyFit ® , COOLMAX ® , and THERMOLITE ® are trademarks of The LYCRA Company.

Contact information

Red Li
+86 21 6330 2011*2362
Red.Li@LYCRA.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Knopp Biosciences Presents Positive Preclinical Data for Lead Neonatal Epilepsy Drug Candidate at 2019 Antiepileptic Drug and Device Trials XV Conference24.5.2019 14:00:00 CESTPressemelding

Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases of high unmet need, today presented in vitro and in vivo data for the company’s lead molecule for the targeted treatment of KCNQ2-neonatal epileptic encephalopathy (KCNQ2-NEE) at the Antiepileptic Drug and Device Trials XV Conference in Miami, Florida. KCNQ2-NEE, a rare infant genetic epilepsy, results from mutations in genes encoding the Kv7.2/Kv7.3 ion channel, leading to frequent seizures and profound developmental delay. The preclinical data were presented by Steven Dworetzky, Ph.D., Knopp’s Chief Scientific Officer, a longtime Kv7 researcher who led the group that first cloned the Kv7.2 and Kv7.3 genes during his former tenure with the Bristol-Myers Squibb Co. Dr. Dworetzky presented results demonstrating the in vitro nanomolar activity of KB-3061 and its significant seizure protection in the maximal electroshock mo

Accelerate Your Business in South Korea Through 2019 K-Startup Grand Challenge24.5.2019 10:20:00 CESTPressemelding

Entrepreneurs from across the globe should set their sights on participating in the 2019 K-Startup Grand Challenge. Supported by the Ministry of SMEs and Startups and National IT Industry Promotion Agency (NIPA) of South Korea, the initiative provides invaluable support and comprehensive resources to early age startups. Applications for the K-Startup Grand Challenge are currently being accepted through June 14, 2019. In order to advance in the program, teams must pass a regional audition. A judging panel of startup ecosystem experts and Korean accelerators will select 40 teams to participate in an enriching 3.5 month-long acceleration program in Korea. The selected teams will have exclusive access to free office space at the Startup Campus in Pangyo Techno Valley, one-on-one mentoring, information sessions, coaching on Korean and Asian business culture and the chance to attend insightful seminars on accounting regulations to tax laws, patents and more. Opportunities for networking with

New Investigational Clinical Data for Ipsen’s Oncology Products in 11 Solid Tumor Types to Be Presented at 2019 ASCO Annual Meeting24.5.2019 05:00:00 CESTPressemelding

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced that new data from clinical studies on investigational uses of cancer medicines cabozantinib (Cabometyx®), liposomal irinotecan (Onivyde®), and lanreotide autogel (Somatuline®, marketed as Somatuline Depot® in the United States) will be presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting. The meeting takes place in Chicago, Illinois, U.S., 31 May–4 June 2019; data featuring Ipsen medicines includes: New data from the Phase 3 CELESTIAL trial on the association of adverse events with efficacy outcomes for cabozantinib in patients with advanced hepatocellular carcinoma Overview of the Phase 3 COSMIC-312 trial of cabozantinib in combination with atezolizumab vs sorafenib in patients with advanced hepatocellular carcinoma who have not received previous systemic anticancer therapy First Phase 2 data from the CaboGIST study (trial 1317) from the European Organization for Research and Treatment of

The Posiflex Group Showcases an Ecosystem of Connected Solution Endpoints with IoT Remote Monitoring at Computex 201924.5.2019 01:00:00 CESTPressemelding

For the Computex 2019 show, The Posiflex Group is featuring leading solution technology from the family of brands as a fully Serviced IoT Ecosystem. Solution end points include: Connected Modular Kiosks, POS Terminals, and Digital Signage solutions from Posiflex and KIOSK Information Systems Smart Medical Displays with gesture controls from Portwell Connected Gaming Solutions with Player Tracking Technology from Portwell subsidiary, Ganlot The booth display is based on common field service endpoints represented in a European Manor Destination Resort setting. Field solutions for an array of vertical market applications include QSR ordering, cinema ticketing, fashion retail customer loyalty, interactive signage, hotel / medical center check-in and bill pay, as well as casino gaming technology. This year, in addition to their renowned POS product suite, Posiflex will be featuring newly introduced Modular Kiosk platforms (co-designed by KIOSK and Posiflex), which are configure-to-order sta

Audi China President Thomas Owsianski to Keynote at CES Asia 201923.5.2019 20:00:00 CESTPressemelding

The Consumer Technology Association (CTA)TM today announced that Thomas Owsianski, president of Audi China, will deliver a keynote address at the upcoming CES Asia 2019. Now in its fifth year, CES Asia will run June 11-13, 2019 at the Shanghai New International Expo Centre (SNIEC) in Shanghai, China. Thomas Owsianski’s keynote is scheduled for 4 PM, Tuesday, June 11, where he will unveil Audi’s vision in transforming mobility from a driving experience to a digital adventure. Mr. Owsianski joined the top management team of Audi China in August 2018 and was named President in October 2018. “Audi has been at the forefront of driving global transformation in the automotive industry through their breakthrough advancements in technology,” said Karen Chupka, executive vice president, CES. “Innovation has revolutionized the transportation experience, and we welcome Mr. Owsianski to the CES Asia stage to share Audi’s vision for the future of global mobility.” Throughout Asia and beyond, technol

ITechLaw Publishes New Book and Opens Global Public Comment Period on Draft Principles for Responsible Artificial Intelligence23.5.2019 19:11:00 CESTPressemelding

The International Technology Law Association (ITechLaw) has published Responsible AI: A Global Policy Framework, a new book that provides an in-depth review and eight discussion principles that address some of the hottest technology and moral issues of responsible development, deployment and use of artificial intelligence. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190523005752/en/ ITechLaw releases new book, Responsible AI: A Global Policy Framework, and opens public comment period. (Photo: Business Wire) Written by a multi-disciplinary group of 54 technology law experts, industry representatives and researchers from 16 countries, the book offers an actionable framework built on the following principles: Ethical Purpose and Societal Benefit, Accountability, Transparency and Explainability, Fairness and Non-discrimination, Safety and Reliability, Open Data and Fair Competition, Privacy, and AI and Intellectual Property.